DCGI approves commercial launch of Tata Group's low cost Covid-19 test 'Feluda'

The Tata CRISPR test achieves accuracy levels of traditional RT-PCR tests with quicker turnaround time, less expensive equipment and better ease of use.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news